Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer
1. While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the...
Pharma
Mirum: Ctexli reduces cholesterol metabolite build-up in patients with cerebrotendinous xanthomatosis
Ctexli significantly reduced levels of two atypical cholesterol metabolites usually elevated in patients with cerebrotendinous xanthomatosis (CTX) compared to the...
Increased tirzepatide use for glycemic and weight control since United States market entry
1. In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval in the United States...
Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer
1. In this randomized controlled trial, in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced...
Patient values and preferences when treating acute episodic migraine
1. In this rapid review, patients valued effectiveness for treating pain more highly than other attributes such as avoiding harm...
Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule
Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial hypertension...
Triptans may be the most effective treatments available for acute episodic migraine
1. In this systematic review and meta-analysis, the combination of triptans and non-steroidal anti-inflammatory drugs (NSAIDs) was the most effective...
Evidence gap for acute pain outcomes in opioid use disorder
1. In this systematic review, evidence for the efficacy of acute pain interventions on individuals with opioid use disorder was...
Venetoclax plus azacitidine demonstrating efficacy for high-risk myelodysplastic syndromes
1. In patients with treatment-naive high-risk myelodysplastic syndromes (HR MDS), the use of venetoclax (14 days) plus azacitidine was well...
![Oral amoxicillin as effective as injectable benzylpenicillin-gentamicin for infants with infection in which referral not possible [AFRINEST Trial]](https://www.2minutemedicine.com/wp-content/uploads/2015/04/NOVAMOXIN_antibiotic-350x250.jpg)
Seven days of antibiotic treatment non-inferior to 14 days for bloodstream infections
1. In this randomized controlled trial, among hospitalized patients with a bloodstream infection, seven days of antibiotic treatment was found...